Previous Article | Next Article 
Molecular and Cellular Biology, August 1999, p. 5659-5674, Vol. 19, No. 8
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Bcl-2 and Bcl-XL Block
Thapsigargin-Induced Nitric Oxide Generation, c-Jun
NH2-Terminal Kinase Activity, and Apoptosis
Rakesh K.
Srivastava,1,*
Steven J.
Sollott,2
Leila
Khan,1
Richard
Hansford,3
Edward G.
Lakatta,2 and
Dan L.
Longo1
Laboratory of
Immunology,1 Laboratory of
Cardiovascular Sciences,2 and Laboratory
of Molecular Genetics,3 Intramural Research
Program, National Institute on Aging, National Institutes of
Health, Baltimore, Maryland 21224-6825
Received 31 August 1998/Returned for modification 27 October
1998/Accepted 29 April 1999
 |
ABSTRACT |
The proteins Bcl-2 and Bcl-XL prevent apoptosis, but
their mechanism of action is unclear. We examined the role of Bcl-2 and Bcl-XL in the regulation of cytosolic Ca2+,
nitric oxide production (NO), c-Jun NH2-terminal kinase
(JNK) activation, and apoptosis in Jurkat T cells. Thapsigargin (TG), an inhibitor of the endoplasmic reticulum-associated Ca2+
ATPase, was used to disrupt Ca2+ homeostasis. TG acutely
elevated intracellular free Ca2+ and mitochondrial
Ca2+ levels and induced NO production and apoptosis in
Jurkat cells transfected with vector (JT/Neo). Buffering of this
Ca2+ response with
1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA-AM) or inhibiting NO synthase activity with NG-nitro-L-arginine
methyl ester hydrochloride (L-NAME) blocked TG-induced NO
production and apoptosis in JT/Neo cells. By contrast, while TG
produced comparable early changes in the Ca2+ level (i.e.,
within 3 h) in Jurkat cells overexpressing Bcl-2 and
Bcl-XL (JT/Bcl-2 or JT/Bcl-XL), NO production,
late (36-h) Ca2+ accumulation, and apoptosis were
dramatically reduced compared to those in JT/Neo cells. Exposure of
JT/Bcl-2 and JT/Bcl-XL cells to the NO donor,
S-nitroso-N-acetylpenacillamine (SNAP) resulted in apoptosis comparable to that seen in JT/Neo cells. TG also activated
the JNK pathway, which was blocked by L-NAME. Transient expression of a dominant negative mutant SEK1 (Lys
Arg), an upstream kinase of JNK, prevented both TG-induced JNK activation and apoptosis. A dominant negative c-Jun mutant also reduced TG-induced apoptosis. Overexpression of Bcl-2 or Bcl-XL inhibited TG-induced loss
in mitochondrial membrane potential, release of cytochrome
c, and activation of caspase-3 and JNK. Inhibition of
caspase-3 activation blocked TG-induced JNK activation, suggesting that
JNK activation occurred downstream of caspase-3. Thus, TG-induced
Ca2+ release leads to NO generation followed by
mitochondrial changes including cytochrome c release and
caspase-3 activation. Caspase-3 activation leads to activation of the
JNK pathway and apoptosis. In summary, Ca2+-dependent
activation of NO production mediates apoptosis after TG exposure in
JT/Neo cells. JT/Bcl-2 and JT/Bcl-XL cells are susceptible
to NO-mediated apoptosis, but Bcl-2 and Bcl-XL protect the
cells against TG-induced apoptosis by negatively regulating Ca2+-sensitive NO synthase activity or expression.
 |
INTRODUCTION |
Apoptosis (programmed cell death) is
an important physiological process, and when dysregulated, it
contributes to the pathogenesis of a variety of diseases including
cancer, autoimmunity, and neurodegenerative disorders (22,
61). Apoptosis results from the action of a genetically encoded
suicide program that leads to a series of characteristic morphological
and biochemical changes (22, 60, 70). These changes include
activation of caspases, mitochondrial depolarization, loss of cell
volume, chromatin condensation, and nucleosomal DNA fragmentation
(10, 22, 60, 70). Among the growing number of genes that are
understood to regulate apoptosis is the Bcl-2 family of genes (5,
51, 53). Some of the proteins within this family, including Bcl-2
and Bcl-XL, inhibit apoptosis, and others, such as Bax and
Bak, promote apoptosis and in some instances are sufficient to cause
apoptosis independent of additional signals (49, 51, 53).
Bcl-2 and related antiapoptotic proteins appear to act in part by
dimerizing with a proapoptotic molecule (e.g., Bax) and interfering
with the apoptosis induced by Bax (45, 58).
Several different biochemical changes have been proposed to be the
essential event that commits a cell to undergo apoptosis (46-53). These events include the generation of reactive
oxygen species (ROS), induction of nitric oxide synthase (NOS),
increase in the intracellular calcium level, loss of mitochondrial
membrane potential, cytochrome c redistribution, and caspase
activation (20, 48, 50, 51, 62, 70). All of these
biochemical perturbations can result from alterations in mitochondrial
function (50, 53, 70). In addition, at least two resident
mitochondrial proteins, apoptosis-initiating factor (AIF) and
cytochrome c, have been implicated in the activation of
caspases (34, 52, 59).
It has been shown that Bcl-2 and Bcl-XL may regulate ion
fluxes (2, 19, 31, 32, 37, 38). This concept is supported by
evidence that Bcl-2 overexpression decreases Ca2+ efflux
through the endoplasmic reticulum (ER) membrane following thapsigargin
(TG) treatment (19), prevents Ca2+
redistribution from the ER into the mitochondria following growth factor withdrawal (2), and inhibits apoptosis-associated
Ca2+ waves (31, 37) and nuclear Ca2+
uptake (38). Bcl-2 overexpression also enhances the uptake of calcium by mitochondria (42, 56) and preserves
mitochondrial transmembrane potential (71). These findings
suggest that Bcl-2 might act as a regulator of intracellular
Ca2+ concentration through its interaction with the ER and
mitochondrial membranes. However, it has been hypothesized that Bcl-2
may heterodimerize with Bax and form pores, similar to those made by
bacterial toxins, which can function as channels in the ER and
mitochondrial membranes for ions, proteins, or both (50,
51). With Bcl-2 inducing the closing and Bax stimulating the
opening of the pores, the ratio of Bcl-2 to Bax may determine the
concentration of Ca2+ released into the cytoplasm (50,
51). Recent findings provide strong evidence that
Bcl-XL also regulates ion fluxes. First, the X-ray and
nuclear magnetic resonance spectroscopy structure of Bcl-XL
resembles the physical structure of ion channel-forming bacterial
toxins (41). Second, Bcl-XL forms an ion channel
in synthetic lipid membranes (33, 40). It has been shown
that Bcl-XL forms a cation-selective channel that conducts
sodium but not calcium (31).
Recent evidence suggests that the JNK/SAPK pathway may play an
important role in triggering apoptosis in response to inflammatory cytokines (interleukin-1, tumor necrosis factor alpha), free radicals generated by UV and gamma radiation, or direct application of H2O2 (7, 11, 12, 30, 35, 36, 67). In
response to the above cellular stresses, JNK is strongly activated
(11, 12). Overexpression of dominant negative mutants of
components in the JNK pathway, such as ASK1(K709R), SEK1(Lys
Arg)
(both are upstream kinases), and c-Jun
169 (a downstream target), can
effectively prevent apoptosis (18, 25, 67, 69). Furthermore,
transfection of the constitutively activated forms of ASK1, SEK1, or
c-Jun results in apoptotic cell death (18, 25, 67, 69).
In the present study, we used TG, an ER Ca2+-ATPase
inhibitor, to disrupt calcium homeostasis. The objectives of this study were to investigate (i) the effect of Bcl-2 and Bcl-XL
overexpression on TG-induced intracellular Ca2+
accumulation in Jurkat T lymphocytes and (ii) the intracellular mechanisms mediating TG-induced apoptosis in Jurkat T lymphocytes. Our
results indicate that TG-induced apoptosis results from a transient
increase of intracellular free calcium levels, calcium-dependent nitric
oxide production, cytochrome c redistribution, reduction in
mitochondrial membrane potential (
m), and
activation of caspase-3 and the JNK pathway. Overexpression of Bcl-2
and Bcl-XL antagonizes apoptosis early in this pathway by
blocking the capacity of cells to generate nitric oxide.
 |
MATERIALS AND METHODS |
Reagents.
TG and 4',6-diamidino-2-phenylindole (DAPI) were
purchased from Sigma Chemical Co. (St. Louis, Mo.). EGTA, SNAP,
1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl)ester (BAPTA-AM), cyclopiazonic acid (CPA),
and PD098059 were purchased from Calbiochem (La Jolla, Calif.).
Antibody against Bcl-2 was purchased from Oncogene Science (Uniondale,
N.Y.). Antibodies against JNK1, ERK2, and p38 were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, Calif.). Antibodies against
phospho-specific SAPK/JNK, extracellular signal-related kinase (ERK),
and p38 were purchased from New England Biolabs, Inc. (Beverly, Mass.).
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP),
indo-1/AM,3,3'-dihexyloxacarbocyanine iodide [DiOC6(3)], NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME),
NG-methyl-D-arginine acetate salt
(D-NMMA), rhod-2, Mito Tracker Green FM, and
anti-cytochrome oxidase (subunit IV) antibody were purchased from
Molecular Probes, Inc. (Eugene, Oreg.). Anti-cytochrome c
antibody was purchased from Pharmingen (San Diego, Calif.). The
apoptosis detection kit (annexin V-fluorescein and propidium iodide)
was purchased from R & D Systems (Minneapolis, Minn.). Anti-Flag M2
antibody was purchased from Kodak (Rochester, N.Y.). [
-32P]ATP (specific activity, 3,000 Ci/mmol) was
purchased from ICN Pharmaceuticals, Inc. (Irvine, Calif.). The caspase
inhibitors z-DEVD-fmk (CBZ-Asp-Glu-Val-Asp-fluoromethylketone) and
z-VAD-fmk (CBZ-Val-Ala-Asp-fluoromethylketone) were purchased from
Enzyme Systems Products (Livermore, Calif.). Enhanced chemiluminescence Western blot detection reagents were purchased from Amersham Life Sciences Inc. (Arlington Heights, Ill.). Dominant negative SEK1 (Lys
Arg) and glutathione S-transferase (GST)-c-Jun
vectors were provided by J. Kyriakis (Massachusetts General Hospital,
Charlestown, Mass.); pCDFLAG
169 DNA was from J. Ham (University
College London, London, United Kingdom). The protein concentration was
measured with the Micro BCA kit (Pierce, Rockford, Ill.). The
nucleosome enzyme-linked immunosorbent assay (ELISA) kit was purchased
from Oncogene Research Products (Cambridge, Mass.). The caspase-3 assay kit was purchased from Clontech Laboratories, Inc. (Palo Alto, Calif.).
Cells and culture conditions.
Jurkat T cells were obtained
from the American Type Culture Collection (Rockville, Md.). The cells
were cultured at 37°C under 5% CO2 in RPMI 1640 tissue
culture medium (Bio Whittaker Inc., Walkersville, Md.) supplemented
with 2 mM L-glutamine, 10% fetal bovine serum, and 1%
penicillin-streptomycin mixture. The concentration of calcium in RPMI
1640 medium was 1.4 mM. For short-wavelength UV light (UVC) treatment
of cells, the medium was removed and the cells were washed twice with
phosphate-buffered saline. The cells were irradiated at a dose rate of
20 or 40 J/m2 (as described in the figure legends), after
which the original culture medium was added back to the cells.
Transfection of Bcl-2 and Bcl-XL genes.
Jurkat T
lymphocytes (2 × 106) were transfected with
pSFFVneo-Bcl-2, pSFFVneo-Bcl-XL or pSFFV-neo (a gift from
Stanley Korsmeyer, Dana-Farber Cancer Institute, Boston, Mass.) with
Lipofectin (GIBCO BRL, Grand Island, N.Y.). Transduced cells were
selected for 3 weeks in RPMI 1640 medium containing 10% fetal bovine
serum and 1 mg of G418 (Geneticin; GIBCO BRL) per ml. The clones
expressing the highest levels of Bcl-2 and Bcl-XL were used
for this study. Lysates were evaluated for Bcl-2 and Bcl-XL
expression by immunoblot analysis.
For transient transfection, Lipofectin reagent was used to transfect
cDNA plasmids by following the protocol provided by the manufacturer
(GIBCO BRL). After transfection, the cells were incubated with complete
medium for one additional day. These cells were then used for experiments.
Calcium measurements.
For the measurement of intracellular
Ca2+ concentration by flow cytometry, 107 cells
were loaded for 45 min at 37°C with 5 µM indo-1/AM. The cells were
washed, resuspended at 106/ml in HBSS containing 1.4 mM
CaCl2, 10 mM HEPES, and 10% fetal bovine serum, and
maintained at 37°C while being run on the flow cytometer. The cells
were analyzed on a FACStarPlus flow cytometer (Becton
Dickinson) with a Krypton laser with UV optics for excitation of the
indo-1. Optimal Ca2+-sensitive ratios were obtained by
measuring the violet (405-nm) light from calcium-bound dye and blue
(485-nm) emitted light from unbound indo-1. The mean ratios were
calculated over time by using MultiTime Kinetic Software (Phoenix Flow Systems).
For the measurement of intracellular free Ca2+ with the PTI
Deltascan spectrofluorometer (SCAN-1; Photon Technology International), cells were loaded with 5 µM indo-1/AM at 37°C for 45 min in a medium comprising 0.14 M NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 10 mM D-glucose, 1.2 mM
NaH2PO4, 4 mM NaHCO3, 4 mM HEPES,
and 1 mg of albumin per ml. Following loading, the cells were incubated at 2 × 106 cells per ml in the cuvette of a PTI
Deltascan spectrofluorometer in the medium described above but with 20 mM sodium HEPES and no HCO3
as buffer.
Fluorescence was measured at 400 nm (emission maximum from the
Ca2+-bound form of indo-1) and 473 nm (an isobestic point)
(54).
For the measurement of intracellular Ca2+ by confocal
microscopic imaging, cells from each group were attached to glass
slides coated with 3-aminopropyltriethoxysilane (Aldrich, St. Louis, Mo.) and loaded with 5 µM indo-1/AM for 45 min at 37°C. The cells were washed for at least 45 min with Hanks balanced salt solution containing 1.4 mM CaCl2, 10 mM HEPES, and 10% fetal bovine
serum and visualized under a microscope in the presence or absence of TG. Calcium was imaged in fields of 75 to 100 cells by using a Zeiss
LSM 410 inverted confocal microscope with 351-nm excitation from a UV
Ar laser with a 40×/1.2 NA c-APO water immersion lens. Epifluorescence was measured at 400 to 435 nm and 473 to 497 nm on
matched photomultipliers, and the ratio of these channels was used to
estimate the intracellular Ca2+ concentration from an in
vitro Ca2+ calibration curve.
For comparison of whole-cell and mitochondrial Ca2+
responses, cells were dually loaded with indo-1/AM (which distributes
throughout the cell) and the mitochondrion-localizing Ca2+
indicator rhod-2. The cells were incubated with 5 µM rhod-2 for 30 min at 25°C, washed in Hanks balanced salt solution (containing 1.4 mM Ca2+ and 10% fetal bovine serum) for 45 min, and then
incubated with indo-1/AM as described above. Cells dually loaded with
rhod-2 and indo-1/AM remained in indicator-free medium for at least
3 h before being imaged. This method results in selective
mitochondrial loading with rhod-2 (i.e., without significant
extramitochondrial loading). This was confirmed in a parallel group of
cells by colocalization of rhod-2 fluorescence with that of the
mitochondrion-specific probe Mito Tracker Green FM (250 nM for 30 min
at 25°C) and by >95% loss of rhod-2 fluorescence within 5 min after
addition of 1 µM FCCP to the bath (with no significant change in
indo-1/AM fluorescence). Rhod-2 fluorescence was obtained in cells
coloaded with indo-1/AM by excitation at 543 nm from a He-Ne laser,
measuring the emitted fluorescence with a long-pass 570 nm filter.
Rhod-2 fluorescence signals were not calibrated and represent a
qualitative measure of changes in mitochondrial Ca2+. There
was no detectable fluorescence cross talk between the rhod-2 and
indo-1/AM channels. Every cell within the microscopic field was
included in the assessment of Ca2+. Image processing was
performed with MetaMorph (Universal Imaging Corp., West Chester, Pa.)
on a Pentium computer.
Measurement of mitochondrial energization.
Mitochondrial
energization was determined as the retention of the dye
3,3'-dihexyloxacarbocyanine (DiOC6)(3). Cells (5 × 105 in 500 µl of complete RPMI 1640 medium) were loaded
with 100 nM DiOC6(3) during the last 30 min of treatment.
The cells were then pelleted at 700 × g for 10 min.
The supernatant was removed, and the pellet was resuspended and washed
in phosphate-buffered saline (PBS) twice. The pellet was then lysed by
the addition of 600 µl of deionized water followed by
homogenization. The concentration of retained DiOC6(3)
was determined on a fluorescence spectrometer (Cyto Fluor; PerSeptive
Biosystems, Framingham, Mass.) at 480-nm excitation and 510-nm emission
(49).
Subcellular fractionation.
Mitochondrial and cytosolic
(S100) fractions were prepared by resuspending cells in 0.8 ml of
ice-cold buffer A (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM
MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol [DTT],
17 µg of phenylmethylsulfonyl fluoride per ml, 8 µg of aprotinin
per ml, 2 µg of leupeptin per ml [pH 7.4]) (20). The
cells were passed through an ice-cold cylinder cell homogenizer.
Unlysed cells and nuclei were pelleted by a 10-min centrifugation at
750 × g. The supernatant was centrifuged at
10,000 × g for 25 min. This pellet was resuspended in
buffer A and represents the mitochondrial fraction. The supernatant was centrifuged at 100,000 × g for 1 h. The
supernatant from this final centrifugation represents the S100 fraction.
Lysate preparation.
For determination of JNK activity, cells
were collected by centrifugation at 300 × g for 5 min
at 4°C. The cell pellets were washed with cold PBS and solubilized
with ice-cold JNK lysis buffer (25 mM HEPES [pH 7.5], 300 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 20 mM
-glycerophosphate, 0.1 mM sodium orthovanadate, 0.5 mM DTT, 100 µg
of phenylmethylsulfonyl fluoride per ml, 2 µg of leupeptin per ml).
The cellular extract was then centrifuged for 30 min at
1,200 × g to remove debris. The supernatant was used
immediately or aliquoted and stored at
70°C for future use.
For Western blotting, cells were lysed in a buffer containing 10 mM
Tris-HCl (pH 7.6), 150 mM NaCl, 0.5 mM EDTA, 1 mM EGTA, 1% sodium
dodecyl sulfate (SDS), 1 mM sodium orthovanadate, and a mixture of
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg of
pepstatin A per ml, 2 µg of aprotinin per ml). The lysates were then
sonicated for 10 s and centrifuged for 20 min at 1,200 × g. The supernatants were used to perform SDS-polyacrylamide gel
electrophoresis (PAGE) or stored at
70°C.
Measurement of JNK activity.
JNK1 was immunoprecipitated and
kinase activity was measured by using an immunokinase complex assay
with GST-c-Jun as a substrate as described previously (30).
Briefly, cell lysates (200 µg of protein) were first incubated
overnight at 4°C with 10 µg of polyclonal anti-JNK1 and then
incubated with 20 µl of Sepharose A-conjugated protein A for an
additional 1 h. The beads were pelleted and washed three times
with cold PBS containing 1% Nonidet P-40 and 2 mM sodium
orthovanadate, once with cold 100 mM Tris-HCl (pH 7.5) buffer
containing 0.5 M LiCl, and once with cold kinase reaction buffer (12.5 mM morpholinepropanesulfonic acid [MOPS] [pH 7.5], 12.5 mM
-glycerophosphate, 7.5 mM MgCl2, 0.5 mM EGTA, 0.5 mM
NaF, 0.5 mM sodium orthovanadate). The kinase reaction was performed in
the presence of 1 µCi of [
-32P]ATP, 20 µM ATP, 3.3 µM DTT, and 3 µg of substrate GST-c-Jun-(1-135) in kinase
reaction buffer for 30 min at 30°C and stopped by addition of 10 µl
of 5× Laemmli loading buffer. The samples were heated for 5 min at
95°C and analyzed by SDS-PAGE (12% polyacrylamide). Phosphorylated
substrate c-Jun was visualized by autoradiography. The optical density
of autoradiograms was determined with the NIH Image program. The kinase
activity was expressed as fold of control.
Measurement of nitric oxide.
For the measurement of nitric
oxide (NO), the Griess reagent kit (Molecular Probes, Inc.) was used.
This assay involves the use of the Griess diazotization reaction to
spectrophotometrically detect nitrite formed by the spontaneous
oxidation of NO under physiological conditions. The detection limit for
this method is between 0.1 and 1.0 µM nitrite. Nitrite concentrations
were measured in cell lysates.
Western blot analysis.
Equal amounts of lysate protein (40 µg/lane) were subjected to SDS-PAGE with either 10% or 8 to 16%
polyacrylamide gels and electrophoretically transferred to
nitrocellulose. Nitrocellulose blots were first blocked with 10%
nonfat dry milk in TBST buffer (20 mM Tris-HCl [pH 7.4], 500 mM NaCl,
0.01% Tween 20) and then incubated overnight at 4°C with primary
antibody in TBST containing 5% bovine serum albumin. Immunoreactivity
was detected by sequential incubation of horseradish
peroxidase-conjugated secondary antibody, and specific complexes were
detected by the enhanced chemiluminescence technique.
Measurement of caspase-3 activity.
ApoAlert caspase assay
kit (Clontech Laboratories, Inc., Palo Alto, Calif.) was used to
measure caspase-3 activity. The ApoAlert caspase-3 fluorescence assay
kit detects the shift in fluorescence emission of
7-amino-4-trifluoromethyl coumarin (AFC). AFC is conjugated to a
specific tetrapeptide sequence (DEVD-AFC). Normally the conjugate emits
blue light. Upon cleavage of the substrate by protease, the liberated
AFC emits a yellow-green fluorescence at 505 nm. Assays were performed
directly on crude cell lysates as specified by the manufacturer.
Apoptosis.
For detection of apoptotic cells, the cells were
first washed twice with cold PBS and then fixed with 4%
paraformaldehyde for 30 min. The fixed cells were washed again with PBS
and stained with 1 µg of DAPI per ml for 30 min. The apoptotic cells
were examined under a fluorescence microscope. Cells containing
condensed or fragmented nuclei were scored as apoptotic. Data are
expressed as a percentage of apoptotic cells in total counted cells.
For detection of apoptosis by annexin V fluorescence and propidium
iodide staining, a kit was purchased from R & D Systems. We used the
procedure as described by the manufacturer.
Nucleosome ELISA.
The nucleosome ELISA allows the
quantitation of apoptotic cells in vitro by DNA affinity-mediated
capture of free nucleosomes followed by their anti-histone-facilitated
detection. In this assay, mono- and oligonucleosomes are captured on
precoated DNA-binding proteins. Standards were provided in the kit to
measure number of nucleosomes per milliliter. Based on the standard
curve, we measured nucleosomes (units per milliliter) in the cell
lysates. Cells (2 × 106) were seeded into 24-well
plates for 36 h in the presence or absence of various drugs (see
the figure legends). They were harvested for the nucleosome ELISA as
specified by the manufacturer (Oncogene Research Products, Cambridge,
Mass.). Anti-histone 3 biotin-labeled antibody binds to the histone
component of captured nucleosomes and is detected following incubation
with streptavidin-linked horseradish peroxidase (SA-HRP) conjugate. HRP
catalyzes the conversion of colorless tetramethylbenzidine to blue. The
addition of stop solution changes the color to yellow, the intensity of
which is proportional to the number of nucleosomes in the sample.
 |
RESULTS |
Overexpression of Bcl-2 or Bcl-XL does not alter
TG-induced calcium release.
Jurkat T lymphocytes were transfected
with human Bcl-2 (JT/Bcl-2) or Bcl-XL
(JT/Bcl-XL) to measure the effects of these antiapoptotic genes on TG-induced cytoplasmic calcium accumulation. Transfection of
Bcl-2 and Bcl-XL genes in Jurkat T cells resulted in
significant overexpression of these proteins (Fig.
1). Treatment of JT/Neo cells with TG
resulted in a transient increase in the intracellular free calcium
level that varied in a dose-dependent manner (1 to 100 nM) (data not
shown). Overexpression of Bcl-2 or Bcl-XL in Jurkat T cells
had no significant effect on the transient increase in the
intracellular free calcium level induced by 50 nM TG compared to
overexpression of Neo (Fig. 2A).
Pretreatment of Jurkat cells with BAPTA-AM abrogated the transient
increase in intracellular free calcium levels due to TG treatment (data
not shown). We further examined the involvement of extracellular
calcium in TG-induced transient calcium release by using EGTA (an
extracellular calcium chelator), which was added at 2 mM to remove any
contribution of extracellular calcium to the 400-nm emission (Fig. 2B).
TG (500 nM) gave a large and transient increase in the 400-nm/473-nm ratio and hence in cytosolic free Ca2+, reflecting the
release of ER Ca2+ into the cytosol (Fig. 2B). Ionomycin (5 µM) addition released Ca2+ from other cellular
compartments. Subsequent addition of 8 mM EGTA and 12 mM
CaCl2 gave fluorescence emission ratio minimum (Rmin) and maximum (Rmax)
values, respectively (Fig. 2B). We next sought to compare the FCCP- (a
mitochondrial uncoupler) and TG-releasable Ca2+ stores
(Fig. 2C). Addition of the uncoupling agent FCCP (0.25 µM) allowed
the mobilization and visualization of the mitochondrial Ca2+ pool (Fig. 2C). Subsequently added TG (500 nM) gave a
large and transient increase in the cytosolic free Ca2+
concentration (Fig. 2C). These data suggest that intracellular free-Ca2+ store release induced by TG was not affected by
extracellular Ca2+ influx.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Increased levels of Bcl-2 and Bcl-XL in
JT/Bcl-2 and JT/Bcl-XL cells, respectively. Western blots
show the increased expression of Bcl-2 or Bcl-XL in Jurkat
T cells transfected with exogenous full-length human Bcl-2 or
Bcl-XL.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
Transient intracellular calcium release by TG, FCCP, and
ionomycin. (A) JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells were
loaded for 45 min at 37°C with 3 µM indo-1/AM and then treated with
TG (50 nM) and ionomycin (5 µM). The cells were analyzed on a
FACStarPlus flow cytometer (Becton Dickinson) with a
Krypton laser with UV optics for excitation of the Indo-1/AM. Optimal
Ca2+ sensitivity ratios were obtained by measuring the
violet (405-nm) light from calcium-bound dye and blue (485-nm) emitted
light from unbound Indo-1/AM. (B) Intracellular free Ca2+
in Jurkat cells was measured with a PTI Deltascan spectrofluorometer.
EGTA (2 mM) was added to remove any contribution of extracellular
calcium to the 400-nm emission. TG (500 nM) gave a large and transient
increase in 400-nm/473-nm ratio, and hence cytosolic free
Ca2+, reflecting the release of ER Ca2+ into
the cytosol. Addition of 5 µM ionomycin released Ca2+
from other cellular compartments. Subsequent addition of 8 mM EGTA and
12 mM CaCl2 gave Rmin and
Rmax, respectively. (C) Intracellular free
Ca2+ in Jurkat cells was measured with a PTI Deltascan
spectrofluorometer. Addition of the mitochondrial uncoupling agent FCCP
(0.25 µM) allowed the mobilization and visualization of the
mitochondrial Ca2+ pool. The remainder of the experiment
was done by the method described for panel B.
|
|
Since Bcl-2 and Bcl-XL did not block TG-induced transient
intracellular free Ca2+ levels in cells, we sought to
determine the calcium levels in the mitochondria and cytosol at 3 h (Fig. 3). At 3 h, overexpression of Bcl-2 or Bcl-XL had no effect on the level of
mitochondrial or cytosolic free calcium, which was similarly increased
by TG in all cell lines (Fig. 3A and B). However, at 36 h, cells
overexpressing Bcl-2 or Bcl-XL had significantly lower
levels of intracellular free calcium (Fig.
4A). Further, TG-induced apoptosis was
correlated with intracellular calcium levels in excess of 600 nM, which
were correspondingly reduced in JT/Bcl-2 and JT/Bcl-XL
cells (Fig. 4B). The elevated Ca2+ levels at 36 h
occur at a time when the apoptosis process is ongoing in cells not
overexpressing Bcl-2 and Bcl-XL. Thus, the late alterations
in Ca2+ levels are a consequence of apoptosis. Early
calcium fluxes are not influenced by Bcl-2 and Bcl-XL
expression.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
Overexpression of Bcl-2 or Bcl-XL has no
effect on TG-induced changes in mitochondrial and cytosolic
free-calcium levels at 3 h. JT/Neo, JT/Bcl-2, and
JT/Bcl-XL cells were treated with TG (50 nM) for 3 h,
loaded with indo-1/AM and rhod-2, and analyzed for mitochondrial (A)
and cytosolic free (B) calcium levels by confocal imaging microscopy
(see Materials and Methods for details). The data are the means and
standard errors. Significant differences (P < 0.05)
among groups were determined by analysis of variance with multiple
comparisons by the Student-Neuman Keul test and are indicated by
different letters. Histograms denoted by a common letter are not
significantly different in group comparisons. Means among groups
denoted by dissimilar letters are statistically significant.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
Overexpression of Bcl-2 or Bcl-XL prevents
TG-induced intracellular free Ca2+ accumulation and
apoptosis at 36 h. (A) JT/Neo, JT/Bcl-2, and JT/Bcl-XL
cells were treated with 50 nM TG for 36 h, loaded with indo-1/AM,
and analyzed for intracellular free Ca2+ levels by confocal
imaging microscopy. (B) JT/Neo, JT/Bcl-2, and JT/Bcl-XL
cells were treated with TG for 36 h and stained with annexin
V-fluorescein isothiocyanate and propidium iodide to examine apoptotic
cells. The data are the means and standard errors. Significant
differences (P < 0.05) among groups were determined by
analysis of variance with multiple comparisons by the Student-Neuman
Keul test and are indicated by different letters. Histograms denoted by
a common letter are not significantly different in group comparisons.
Means among groups denoted by dissimilar letters are statistically
significant.
|
|
A rise in the intracellular calcium level is necessary for
TG-induced apoptosis.
We first determined the effects of Bcl-2 and
Bcl-XL on TG-induced apoptosis (as measured by nucleosome
ELISA) over time (Fig. 5A). Treatment of
JT/Neo cells with TG (50 nM) resulted in induction of apoptosis which
began after 6 h and increased over a period of 48 h (Fig.
5A). Overexpression of Bcl-2 or Bcl-XL inhibited TG-induced
apoptosis over a period of 48 h (Fig. 5A). To evaluate the
relationship between intracellular calcium levels and apoptosis, we
used irreversible (TG) and reversible (CPA) inhibitors of the ER
calcium-ATPase pump. These compounds are known to increase intracellular calcium levels. Treatment of wild-type Jurkat cells with
TG or CPA resulted in the induction of apoptosis in a dose-dependent manner at 36 h (Fig. 5B and C). We next examined the source of the
calcium that accumulated after TG or CPA treatment. BAPTA-AM was used
to chelate cytoplasmic calcium, and EGTA was used to chelate
extracellular calcium. Cells were pretreated with BAPTA-AM (10 µM)
for 45 min, washed with PBS, and reseeded in culture medium with or
without TG or CPA. BAPTA-AM abolished the apoptotic effects of TG
or CPA (Fig. 5B and C). By contrast, the chelation of extracellular calcium with 2 mM EGTA had no significant effect on TG- or CPA-induced apoptosis (data not shown). These data suggest that intracellular free
calcium accumulation plays a critical initiating role in TG- or
CPA-induced apoptosis.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Inhibition of TG- or CPA-induced apoptosis by chelating
intracellular calcium or overexpressing Bcl-2 and Bcl-XL.
(A) Time course of TG-induced apoptosis in JT/Neo, JT/Bcl-2, and
JT/Bcl-XL cells. Cells were treated with TG (50 nM) for 4, 6, 18, 24, 36, and 48 h. (B and C) Chelation of intracellular
calcium by BAPTA-AM blocks TG- or CPA-induced apoptosis. Cells were
pretreated with BAPTA-AM (10 µM) for 45 min, washed, reseeded and
treated with TG (10, 50, or 100 nM), or CPA (0.1, 1, or 10 µM) for
36 h. (D and E) Overexpression of Bcl-2 or Bcl-XL
blocks TG- or CPA-induced apoptosis. Cells were treated with TG (10, 50, or 100 nM) or CPA (0.1, 1, or 10 µM) for 36 h. A nucleosome
ELISA was used to measure apoptosis.
|
|
Because TG and CPA induced apoptosis in Jurkat cells, we next examined
the effects of Bcl-2 and Bcl-XL overexpression on TG- or
CPA-induced apoptosis (Fig. 5D and E). Treatment of Jurkat cells with
TG or CPA resulted in the induction of apoptosis in a dose-dependent
manner at 36 h. Overexpression of Bcl-2 or Bcl-XL blocks TG- or CPA-induced apoptosis (Fig. 5D and E) in Jurkat cells.
Because Ca2+ release is similar in wild-type and Bcl-2- and
Bcl-XL-overexpressing cells, Bcl-2 and Bcl-XL
must be blocking apoptosis at a point in the pathway downstream of
Ca2+ release.
Bcl-2 or Bcl-XL prevents the release of cytochrome
c.
Mitochondria appear to play an important role in the
early events of apoptosis (4). Both mitochondrial
depolarization and the loss of cytochrome c from the
mitochondrial intermembrane space have been proposed as early central
events in apoptotic cell death (52, 70). Whether cytochrome
c release occurs before the loss of mitochondrial membrane
potential or as a result of the loss of inner membrane potential
remains controversial (29, 59, 70). Since the cell survival
proteins Bcl-2 and Bcl-XL localize to the outer
mitochondrial membrane, the effects of Bcl-2 or Bcl-XL
overexpression on cytochrome c redistribution and
mitochondrial membrane depolarization in response to TG were investigated.
We next determined the presence of cytochrome c in the
cytosolic and mitochondrial fractions of cells treated with TG. The subcellular localization of cytochrome c, which normally
resides in the mitochondrial intermembrane space, was first assessed at various times following TG treatment (Fig.
6A). Treatment of wild-type or JT/Neo
Jurkat cells with TG resulted in the release of cytochrome c
from the mitochondria in a time-dependent manner (Fig. 6A). In Jurkat
cells, the release of cytochrome c began at 2 h and reached a plateau at 4 h (Fig. 6A). At 4 h after 100 nM TG
treatment, Jurkat cells had not yet undergone apoptosis as measured by
DAPI staining (data not shown). We next examined the effects of Bcl-2 and Bcl-XL on the cytochrome c release after
4 h of 100 nM TG treatment (Fig. 6B). There was no cytochrome
c in the cytosol of untreated JT/Neo, JT/Bcl-2, or
JT/Bcl-XL cells (Fig. 6B). When cells were treated with TG
(100 nM) for 4 h, cytochrome c was detected in the
cytosol of JT/Neo cells (Fig. 6B). By contrast, cytochrome c
was not detected in the cytosol of TG-treated JT/Bcl-2 or
JT/Bcl-XL cells (Fig. 6B). The caspase inhibitor z-VAD-fmk did not block TG-induced cytochrome c release from
mitochondria (Fig. 6B). JT/Bcl-2 and JT/Bcl-XL cells were
>92 to 95% viable after 4 h of TG treatment (data not shown). In
contrast to the cytochrome c release, the inner
mitochondrial membrane protein cytochrome oxidase remained in the
mitochondrial fraction in all cell groups under all conditions tested
(Fig. 6B). Thus, Bcl-2 and Bcl-XL appear to act upstream of
mitochondrial cytochrome c release from mitochondria in the
prevention of TG-induced apoptosis.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Bcl-2 and Bcl-XL prevent the redistribution
of cytochrome c in cells undergoing apoptosis. (A) Time
course of cytochrome c release in Jurkat cells treated with
TG. The release of cytochrome c in the cytosolic extract was
determined by Western blot analysis and was quantified by densitometric
scanning of the autoradiograph and plotted against time in hours after
TG treatment. (B) Redistribution of cytochrome c in Bcl-2-
and Bcl-XL-overexpressing Jurkat cells. JT/Neo, JT/Bcl-2,
and JT/Bcl-XL cells were treated with 100 nM TG. Jurkat T
cells were pretreated with the caspase inhibitor z-VAD-fmk (50 µM)
for 1 h prior to addition of TG (right panel). After 3 h, the
cells were mechanically lysed and separated into mitochondrial (M) and
S100 (S) fractions. The amounts of cytochrome c and
cytochrome oxidase (subunit IV) present in each fraction were
determined by Western blot analysis. (C) Bcl-2 or Bcl-XL
blocks TG-induced caspase-3 activation. Jurkat cells were treated with
TG (100 nM) for various times. Caspase-3 activity was measured as
specified by the manufacturer (see Materials and Methods). (D) The
caspase inhibitors z-VAD-fmk and z-DEVD-fmk block TG- and CPA-induced
apoptosis. Jurkat T cells were pretreated with the caspase inhibitor
z-VAD-fmk (50 µM) or z-DEVD-fmk (50 µM) for 1 h and then
treated with TG or CPA for an additional 36 h. Apoptosis was
measured by a nucleosome ELISA.
|
|
The activation of caspases appears to be essential for the
implementation of apoptosis (62). Bcl-2 and
Bcl-XL have recently been proposed to regulate caspase
activation (8). Recent data have shown that cytochrome
c is involved in the activation of caspase(s)
(63). Treatment of JT/Neo cells with 100 nM TG resulted in
an increase in caspase-3 activity (Fig. 6C). Bcl-2 or
Bcl-XL overexpression blocked caspase-3 activation (Fig.
6C). To assess the involvement of caspase(s) in TG- or CPA-induced
apoptosis, we used the caspase inhibitors z-VAD-fmk and z-DEVD-fmk. As
shown above, TG or CPA induced apoptosis in Jurkat cells in a
dose-dependent manner (Fig. 5D and E). In addition, Z-VAD-fmk and
z-DEVD-fmk blocked TG- and CPA-induced apoptosis in Jurkat cells (Fig.
6D). These data are consistent with the hypothesis that the inhibition of cytochrome c release in Bcl-2- and
Bcl-XL-overexpressing cells results in a failure to
activate caspase-3.
TG causes mitochondrial depolarization that is inhibited by Bcl-2
or Bcl-XL but not by z-DEVD-fmk.
Mitochondrial
permeability transition (MPT) refers to the regulated opening of a
large, nonspecific pore in the inner mitochondrial membrane
(4). The MPT causes the loss of the mitochondrial membrane
potential (
m) (44). The
fluorescent dye DiOC6(3) localizes to mitochondria, and the
MPT reduces the accumulation of DiOC6(3) as a consequence
of the loss of 
m (66). Treatment of JT/Neo cells with TG produced a steady decline in 
m (Fig. 7A).
Within 4 h, more than 30% of the dye was lost from the cells
(Fig. 7A). The time-dependent loss of DiOC6(3) fluorescence
in Jurkat cells due to TG treatment was prevented by the overexpression
of Bcl-2 or Bcl-XL (Fig. 7A). Consistent with its inability
to prevent the loss of cytochrome c release (Fig. 6B), the
caspase inhibitor z-DEVD-fmk had no effect on TG-induced mitochondrial
depolarization (14) (Fig. 7B). These data suggest that Bcl-2
and Bcl-XL regulate the release of mitochondrial factors that are required for caspase activation, and the caspases act downstream of mitochondrial apoptotic events since the caspase inhibitors have no effect on cytochrome c release and loss
of 
m caused by TG.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 7.
TG causes mitochondrial depolarization that is inhibited
by Bcl-2 or Bcl-XL but not by the caspase inhibitor
z-DEVD-fmk. (A) JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells were
treated with TG (100 nM) for various times or left untreated. During
the last 30 min of treatment, DiOC6(3) was added. An
aliquot of the cells was used for the determination of cell-associated
DiOC6(3) fluorescence. (B) Jurkat cells were pretreated for
30 min with z-DEVD-fmk before addition of 100 nM TG, and uptake of
DiOC6(3) was determined at the times indicated.
|
|
TG activates the JNK/SAPK pathway.
Activation of the JNK
pathway has been implicated in initiating apoptosis in response to
several stimuli (6, 7, 11, 12, 30, 35, 67). To test the
hypothesis that TG-induced apoptosis may involve the JNK pathway, we
examined the effects of TG, which include JNK activation and the
phosphorylation of c-Jun, on this pathway.
We first characterized the JNK assay by using wild-type Jurkat cells
(Fig. 8). The kinase activity increased
between 0 and 4 h after TG treatment and reached a plateau
thereafter (Fig. 8A). The kinase activity was also increased with the
various doses of TG treatment over 3 h (Fig. 8B). Thus, TG-induced
apoptosis includes JNK activation. Based on these results, we used 100 nM TG and 4-h incubation times for further experiments.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 8.
TG induces JNK activation in a time- and dose-dependent
manner. Jurkat T lymphocytes were treated with TG for various times.
The cell lysates were prepared and immunoprecipitated with 10 µg of
polyclonal anti-JNK1 antibody followed by 20 µl of Sepharose
A-conjugated protein A. The kinase reaction was performed by the
procedures described in Materials and Methods. (A) Time course of the
kinase reaction. The top figure represents the autoradiogram of
[ -32P]ATP incorporation into exogenous
GST-c-Jun-(1-135). The amount of cell lysate used was 200 µg of
protein in each lane. The bottom figure is a plot of JNK activity
against time. The values in this figure are means and standard errors
of three determinations. (B) Dose response of JNK activation. Anti-JNK1
immunocomplexes were obtained with lysates of cells treated with
various doses of TG for 3 h. The JNK assay was performed as
described in Materials and Methods. The top figure is a representative
autoradiogram of three independent experiments. The bottom figure shows
quantified data from three determinations (means and standard
errors).
|
|
Overexpression of Bcl-2 or Bcl-XL blocks JNK/SAPK
activation by TG.
We next examined the effects of TG on the
activation of mitogen-activated protein (MAP) kinases (JNK, ERK, and
p38) by using JNK, ERK, and p38 antibodies specific for the
phosphorylated and activated forms of these kinases. Western blot
analyses revealed that TG (100 nM for 4 h) activated the JNK
pathway in JT/Neo cells and that the activation of JNK was blocked in
JT/Bcl-2 and JT/Bcl-XL cells (Fig.
9A). This phospho-specific antibody can
recognize both phospho-JNK1 (46 kDa, a lower band) and phospho-JNK2 (54 kDa, a higher band) (Fig. 9A). The immunoblot with JNK1-specific antibody revealed that the total JNK1 protein level did not change significantly in JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells
(Fig. 9A). Only modest activation of ERK was noted in response to TG
(100 nM) treatment, and the level did not differ significantly in
JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells (Fig. 9B). The
immunoblot with ERK2-specific antibody revealed that ERK2 protein did
not change in JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells (Fig.
9B). To evaluate the involvement of ERK in TG-induced apoptosis, we
used a specific inhibitor of MEK1/2 (PD098059), kinases upstream of
ERK1/2. Cells were pretreated with 10 µM MEK1/2 inhibitor (PD098059)
for 1 h and then incubated with 100 nM TG for 36 h. The ERK
inhibitor PD098059 had no effect on TG-induced apoptosis (data not
shown), suggesting that the modest activation of ERK is a consequence
rather than the cause of TG-induced apoptosis. Interestingly, p38 was
not activated in response to 100 nM TG treatment and total p38 levels
did not change in JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells
(Fig. 9C). In addition, p38 was activated in response to UV light (UVC)
treatment. These data suggest that TG activates the JNK pathway and
that TG-induced JNK activation can be blocked by Bcl-2 or
Bcl-XL overexpression.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 9.
Overexpression of Bcl-2 or Bcl-XL blocks the
JNK pathway. (A) JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells were
treated with 100 nM TG for 4 h. The Western blots (IB) were
performed with antibody specific to phosphoactive JNK (top panel) and
anti-JNK1 antibody (bottom panel). (B) Cells were treated as described
in panel A. The Western blots were performed with antibody specific to
phosphoactive ERK (top panel) and anti-ERK2 antibody (bottom panel).
(C) Cells were treated as described in panel A. The Western blots were
performed with antibody specific to phosphoactive p38 (top panel) and
anti-p38 antibody (bottom panel). For a positive control, a group of
cells was also exposed to UVC (20 J/m2).
|
|
JNK/SAPK signaling mediates TG-induced apoptosis.
As mentioned
previously, the JNK/SAPK pathway involves an orderly activation of
proteins, MEKK1, SEK1, JNK, and c-Jun (11, 12, 25). SEK1
kinase activates JNK, and c-Jun is the substrate of JNK. We assessed
the role of the JNK pathway in TG-induced apoptosis by using a dominant
negative SEK1 (Lys
Arg) mutant and a c-Jun dominant negative mutant
Flag
169.
pEBG-SEK1 (Lys
Arg) is a dominant negative kinase-inactive construct
(67). In U937 cells, its transfection efficiency is about
39% (67). Expression of SEK1 (Lys
Arg) in U937 cells
inhibits ceramide- or H2O2-induced endogenous
JNK activity by 50% and completely inhibits the co-transfected
hemagglutinin-tagged JNK (67). We transiently transfected
this GST-tagged SEK1 dominant negative mutant into Jurkat cells. Its
expression was detected by anti-GST immunoblotting (data not shown). By
cotransfection with pCMV carrying the lacZ gene and staining
with 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal), we calculated that the transfection efficiency was about 65 to
70% in Jurkat cells. Overexpression of this SEK-1 (Lys
Arg) mutant
inhibited TG (100 nM for 4 h)-induced endogenous JNK activity by
76% compared with the control group (Fig.
10A). Accordingly, transiently
transfected SEK-1 (Lys
Arg) also inhibited TG-induced phosphorylation
of JNK1 as detected with the anti-phospho-JNK antibody (Fig. 10A).
Furthermore, the transfection of SEK1 mutant also significantly
inhibited apoptosis as measured by DAPI staining (100 nM TG for 36 h). Thus, these observations suggest that SEK1-JNK1-c-Jun activation
is involved in TG-induced apoptosis.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 10.
Block of the JNK pathway inhibits TG-induced apoptosis.
(A) A dominant negative mutant SEK1(Lys Arg) inhibits activation of
the JNK pathway and apoptosis induced by TG. Jurkat cells were plated
on 60-mm dishes and transfected with a total of 2 µg of DNA of either
empty vector ( ) or mutated SEK1 (+) per ml. After 1 day, the cells
were incubated with 100 nM TG (+) or vehicle ( ) for 4 h. The
cell lysates were prepared. The JNK activity and immunoblots (IB) were
determined as described in the text. Antibody against phospho-specific
JNK can recognize both phosphorylated JNK1 (46 kDa, lower band) and
phosphorylated JNK2 (54 kDa, upper band). For apoptosis, the cells were
treated with TG (100 nM) for 36 h and stained with DAPI as
described in Materials and Methods. The figure shows that transfection
of a dominant negative SEK1 mutant significantly inhibited JNK
activation and apoptosis by TG. The data are means and standard errors.
Significant differences (P < 0.05) among groups were
determined by analysis of variance with multiple comparisons by the
Student-Neuman Keul test and are indicated by different letters.
Histograms denoted by a common letter are not significantly different
in group comparisons. Means among groups denoted by dissimilar letters
are statistically significant. (B) Dominant negative c-Jun mutant
Flag 169 reduces TG-induced apoptosis. (Left) Immunoblotting of
transfected Flag 169 (2 µg/ml DNA) or its empty vector (2 µg/ml)
Jurkat cells with monoclonal anti-Flag (M2, 1:1,000). (Right)
Percentage of apoptotic Jurkat cells due to 100 nM TG treatment for
36 h under conditions of either transfected Flag 169 (+, 2 µg/ml) or its empty vector ( , 2 µg/ml). The data are means and
standard errors. Significant differences (P < 0.05)
among groups were determined by analysis of variance with multiple
comparisons by the Student-Neuman Keul test and are indicated by
different letters. Histograms denoted by a common letter are not
significantly different in group comparisons. Means among groups
denoted by dissimilar letters are statistically significant. (C)
Chelation of cytosolic calcium with BAPTA-AM blocks TG-induced
phosphorylation and activation of JNK. Jurkat cells were pretreated
with 10 µM BAPTA-AM for 45 min and then subjected to 100 nM TG
treatment for 4 h. JNK activity was measured as described in
Materials and Methods. The results demonstrate that chelation of
cytosolic calcium with BAPTA-AM blocks TG-induced phosphorylation and
activation of JNK.
|
|
Next, we examined the effects of a dominant negative c-Jun mutant,
FLAG169, on TG-induced apoptosis. This c-Jun 169 lacks the ability to
activate transcription but is still capable of dimerization and binds
to DNA (18, 21). The c-Jun 169 vector is tagged by an
8-amino-acid FLAG epitope in place of NH2-terminal 169, allowing its expression to be monitored by Western immunoblotting or
immunocytochemistry with monoclonal anti-M2 (18). We
transiently transfected Jurkat cells with this c-Jun 169 and detected
its expression by anti-M2 immunoblotting (Fig. 10B). Its transfection efficiency was about 60 to 70% as determined by both anti-M2
immunocytochemistry and cotransfection with pCMV vector expressing
lacZ. One day after transfection, the cells were exposed to
100 nM TG for 36 h. Compared with the situation for empty
vector-transfected Jurkat cells, c-Jun 169 effectively reduced
TG-induced apoptosis by more than 60% (Fig. 10B). The transfection of
c-Jun 169 itself did not affect cell behavior, since no apoptosis was
observed (Fig. 10B). In accordance with the above data from the
negative SEK1 mutant experiments, the data with dominant negative c-Jun
suggests that TG induces apoptosis through a SEK1, JNK1, and c-Jun pathway.
If the activation of JNK by TG is mediated by an increase in
intracellular calcium levels, buffering of cytosolic calcium should
block such an activation. Figure 5A showed that TG-induced apoptosis
was blocked by the pretreatment of Jurkat cells with BAPTA-AM (10 µM). We therefore investigated whether chelation of intracellular
calcium by BAPTA-AM would block TG-induced JNK activation (Fig. 10C).
Treatment of Jurkat cells with 100 nM TG for 4 h resulted in the
activation of JNK (Fig. 10C). When cells were pretreated with BAPTA-AM,
TG did not cause JNK activation (Fig. 10C). These results support the
idea that the activation and phosphorylation of JNK by TG may be
triggered by an increase in cytosolic calcium.
JNK activation occurs in response to changes in mitochondrial
functions.
We next evaluated whether JNK is activated before or
after changes in mitochondrial functions in response to TG treatment. Transfection of a dominant negative SEK1(Lys
Arg) mutant did not block TG-induced cytochrome c release into the cytosol (Fig.
11A), suggesting that JNK activity is
not required for cytochrome c release. This raises a
possibility of JNK activation in response to changes in
post-mitochondrial events such as caspase activation (47,
68). Pretreatment of Jurkat cells with the caspase inhibitor z-VAD-fmk or z-DEVD-fmk blocked TG-induced JNK activation (Fig. 11B).
Thus, JNK activation depends upon prior caspase activation.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 11.
Mitochondrial events activate JNK and induce apoptosis.
(A) A dominant negative mutant SEK1(Lys Arg) does not inhibit
TG-induced cytochrome c release from mitochondria to the
cytosol. Jurkat cells were plated on 60-mm dishes and transfected with
a total of 2 µg of DNA of either empty vector (WT) or mutated SEK1
per ml. After 1 day, cells were incubated with 0.1 µM TG (+) or
vehicle ( ) for 4 h. Jurkat cells were mechanically lysed and
separated into mitochondrial (M) and S100 (S) fractions. The amount of
cytochrome c present in each fraction was determined by
Western blot analysis. (B) Caspase inhibitors block TG-induced JNK
activation. Jurkat cells were pretreated with either 50 µM z-VAD-fmk
or 50 µM z-DEVD-fmk for 1 h and then subjected to 0.1 µM TG
treatment for 4 h. At the end of the culture period, the cells
were harvested and lysed and JNK activity was assessed by Western blot
analysis with anti-JNK antibody (phosphospecific). Cells were also
exposed to UVC (20 or 40 J/m2) as a positive control. (C)
The NOS inhibitor L-NAME, but not D-NMMA (an
inactive compound), inhibits TG-induced JNK activation. Jurkat cells
were pretreated with either L-NAME (10 mM) or
D-NMMA (10 mM) for 45 min and then subjected to 0.1 µM TG
treatment for 4 h. JNK activity was measured as described in
Materials and Methods. (D) L-NAME, but not
D-NMMA, inhibits TG-induced apoptosis. Jurkat cells were
pretreated with either L-NAME (10 mM) or D-NMMA
(10 mM) for 45 min and then subjected to 0.1 µM TG treatment for
36 h and stained with DAPI. The data are means and standard
errors. Significant differences (P < 0.05) among
groups were determined by analysis of variance with multiple
comparisons by the Student-Neuman Keul test and are indicated by
different letters. Histograms denoted by a common letter are not
significantly different in group comparisons. Means among groups
denoted by dissimilar letters are statistically significant.
|
|
Although TG-induced apoptosis may involve multiple mechanisms, recent
evidence suggests that generation of nitric oxide due to various
stimuli may play an essential role in induction of apoptosis (1,
9, 14). Given that the TG-induced apoptosis is mediated by the
JNK pathway (Fig. 10), we examined the effects of nitric oxide on
TG-induced JNK activation and subsequent apoptosis. To explore the
involvement of nitric oxide in TG-induced JNK activation and apoptosis,
we used the NOS inhibitor L-NAME (Fig. 11C and D). The
cells were first treated with L-NAME (10 mM) or
D-NMMA (an arginine analogue that does not block NOS) (10 mM) or left untreated (control) for 45 min. These cells were then
exposed to 100 nM TG for either 4 or 36 h to determine JNK
activity and apoptotic cell death, respectively. Pretreatment of Jurkat
cells with L-NAME inhibited TG-induced JNK activation and
apoptosis (Fig. 11C and D). The inactive D-NMMA had no
effect on TG-induced JNK activation and apoptosis (Fig. 11C and D).
Thus, a NOS inhibitor protects against TG-induced apoptosis and
prevents JNK activation, providing another piece of evidence for an
essential role of JNK activation via NO in TG-induced apoptosis.
Bcl-2 and Bcl-XL do not alter the nitric oxide
sensitivity of Jurkat cells, but block the ability to generate nitric
oxide in response to TG treatment.
Since L-NAME
blocked TG-induced apoptosis, we reasoned that NO was essential to the
process. To assess whether Bcl-2 and Bcl-XL were protecting
the cells against NO-mediated toxicity, we exposed all these cell
lines, JT/Neo, JT/Bcl-2, and JT/Bcl-XL, to the NO donor
compound SNAP, which generates NO extracellularly in the culture
medium, with or without added TG. As shown in Fig. 12A, TG induces apoptosis of JT/Neo but
not JT/Bcl-2 or JT/Bcl-XL cells; however, SNAP is toxic to
all three cell lines. The level of SNAP sensitivity is not greatly
affected by TG. Thus, the overexpression of Bcl-2 and
Bcl-XL does not influence the ability of the cells to
survive NO exposure.


View larger version (72K):
[in this window]
[in a new window]
|
FIG. 12.
Inhibition of TG-induced nitric oxide production and
apoptosis by Bcl-2 and Bcl-XL in Jurkat cells. (A) Bcl-2-
and Bcl-XL-transfected cells are sensitive to apoptosis
induced by exposure to SNAP (a nitric oxide donor) but not to TG.
JT/Neo, JT/Bcl-2, and JT/Bcl-XL cells were pretreated with
either 10 mM L-NAME or 10 mM D-NMMA for 45 min
and then subjected to 0.1 µM TG treatment for 24 h and stained
with DAPI. The data are means and standard errors. Significant
differences (P < 0.05) among groups were determined by
analysis of variance with multiple comparisons by the Student-Neuman
Keul test and are indicated by different letters. Histograms denoted by
a common letter are not significantly different in group comparisons.
Means among groups denoted by dissimilar letters are statistically
significant. (B) Treatment of cells with L-NAME or BAPTA-AM
or overexpression of Bcl-2 or Bcl-XL blocks endogenous
production of nitric oxide after TG exposure. JT/Neo, JT/Bcl-2, and
JT/Bcl-XL cells were pretreated with 10 mM
L-NAME, 10 mM D-NMMA, or 10 µM BAPTA-AM, for
45 min and then subjected to 0.1 µM TG or 150 nM SNAP treatment for
1, 2, and 6 h. At the end of culture period, the cells were
harvested, washed, and lysed. The nitrite concentration in the cell
lysate (100 µg) was measured with the Greiss reagent kit (see
Materials and Methods for details). No measurable nitrite was detected
in the culture medium.
|
|
There were no differences among the cell lines in NO sensitivity or in
Ca2+ release as a consequence of TG. Therefore, we sought
to examine nitric oxide production by JT/Neo, JT/Bcl-2, and
JT/Bcl-XL cells exposed to TG (Fig. 12B). Nitric oxide
concentration was assessed by measuring the nitrite concentration in
cells at 1, 2, and 6 h by the Griess assay. Treatment of cells
with TG resulted in nitrite production as early as 1 h, and the
level of nitrite increased over a period of 6 h (Fig. 12B). As
expected, L-NAME (10 mM) and BAPTA-AM (10 µM) blocked
TG-induced nitrite production in JT/Neo, JT/Bcl-2, and
JT/Bcl-XL cells at 1, 2, and 6 h. The overexpression of Bcl-2 or Bcl-XL inhibited TG-induced nitrite production
(Fig. 12B). The inactive inhibitor of NOS, D-NMMA, had no
effect on TG-induced nitrite production. The extracellular nitric oxide
donor, SNAP, increased nitrite levels 2.5- to 3-fold in JT/Neo cells.
Overexpression of Bcl-2 or Bcl-XL had no effect on
SNAP-induced nitrite production. These results suggest that Bcl-2 and
Bcl-XL can block the calcium-induced endogenous production
of nitric oxide by TG and that the prevention of NO generation is the
mechanism by which these proteins protect cells from TG-induced apoptosis.
 |
DISCUSSION |
In this paper, we demonstrate that TG induces apoptosis through a
pathway involving an increase in intracellular calcium levels, generation of nitric oxide, a reduction in mitochondrial membrane potential, release of mitochondrial cytochrome c, and
activation of caspase-3 and the JNK pathway. We also present evidence
that overexpression of Bcl-2 or Bcl-XL in Jurkat T
lymphocytes had no significant effect on the TG-induced mitochondrial
and intracellular free calcium levels up to 3 h. The amplitude of
intracellular Ca2+ transiently induced by TG was not
affected by the presence or absence of extracellular Ca2+,
indicating that TG must be acting to release intracellular
Ca2+ stores. The data suggest that apoptosis is a
consequence of the increase in calcium level because preventing the
increase directly by chelating intracellular calcium prevents
apoptosis. TG induces nitric oxide production and JNK activation, both
of which precede apoptosis. The JNK activation increases after 2 h
of treatment with TG, whereas apoptotic cells begin to appear after
8 h of exposure of the cells to TG. TG-induced activation of the
JNK pathway tightly correlates with the subsequent apoptosis in a concentration-dependent manner. In addition, a dominant negative SEK1
mutant can block TG-induced JNK activation and subsequent phosphorylation of c-Jun as well as apoptosis. Consistent with this
result, a dominant negative c-Jun mutant, which blocks c-Jun activation, also inhibits apoptotic cell death by TG. Finally, overexpression of Bcl-2 or Bcl-XL blocks production of
nitric oxide, release of cytochrome c, reduction in

m, and activation of caspase-3 and the JNK
pathway in Jurkat cells treated with TG. Thus, our data suggest a model
by which TG causes increased intracellular Ca2+ levels,
leading to generation of nitric oxide. The nitric oxide then leads to
the release of cytochrome c from the mitochondria and a
reduction in 
m. The cytochrome
c results in activation of caspase-3, and caspase-3
activates the JNK pathway, resulting in apoptosis (Fig.
13). Blocking any of the steps, calcium
release (BAPTA-AM), nitric oxide production (L-NAME and,
for the first time, Bcl-2 and Bcl-XL), caspase activation
(z-VAD-fmk, z-DEVD-fmk), or JNK activation (dominant negative SEK-1 and
c-Jun) blocks the TG-induced apoptosis.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 13.
Model showing that disruption of calcium homeostasis
leads to apoptosis by altering mitochondrial functions and inducing JNK
activation. Disruption of calcium homeostasis by TG increases the
intracellular free calcium level and promotes nitric oxide generation
in the mitochondria and loss in mitochondrial membrane potential,
leading to cytochrome c release, caspase-3 activation,
induction of JNK activity, and apoptosis. Overexpression of Bcl-2 or
Bcl-XL has no effect on the transient intracellular calcium
levels but inhibits nitric oxide production, reduction in
 m, and cytochrome c release,
leading to caspase-3 activation and apoptosis.
|
|
In contrast to our findings, it has been reported that Bcl-2
overexpression attenuates the transient Ca2+ release in
response to TG treatment (19, 31). The ER membrane channel
through which Ca2+ flows after TG treatment has not been
identified but appears to be distinct from the Ca2+ release
channel associated with the inositol 1,4,5-triphosphate receptor
(3, 56). Identification of ion channels associated with the
ER membrane may be a requisite for fully understanding the mechanism of
action of Bcl-2. He et al. (19) proposed that Bcl-2 may
facilitate Ca2+ reuptake in the ER by forming pores when
the Ca2+-ATPase is inhibited by TG. Since Bcl-2 and
Bcl-XL are also localized to the mitochondrial membrane,
mitochondria may play a role in calcium homeostasis (22, 24,
31) and free radical scavenging and antioxidant activity
(23, 26, 55, 71). These activities might be cooperative, in
light of the relationship between oxidant stress and calcium release
leading to apoptosis. In the present study, Bcl-2 and
Bcl-XL overexpression had no effect on mitochondrial and
intracellular free calcium levels up to 3 h after TG treatment. However, these proteins affected the generation of nitric oxide as a
consequence of calcium release and thereby prevented downstream events
including the release of cytochrome c from the mitochondria and activation of caspase-3 after TG treatment. If Bcl-2 and
Bcl-XL have an influence on calcium flux, we could not
detect it.
Our results indicate that TG induces a persistent activation of the JNK
enzyme, which may play a critical role in the apoptotic suicide
program. TG strongly stimulates JNK activity after a 4-h exposure of
cells, and the kinase activity persists throughout apoptosis. The
sustained JNK activation is Ca2+ dependent and may serve as
a death signal in TG-induced apoptosis. Chelation of intracellular
calcium with BAPTA-AM prevented the TG-induced JNK activation and
apoptosis, confirming the early mediating role of calcium during
TG-induced apoptosis. The lag time between the calcium signal and the
activation of JNK is consistent with a role for calcium as an upstream
activator of JNK. In agreement with this view, a similar longer
stimulation of the JNK enzyme was also observed in some environmental
stress-induced forms of apoptosis. For example, exposure of Jurkat
cells to lethal doses of
and UVC radiation rapidly increases JNK
activity after 30 min, and the activation can last at least 12 h
without having a significant effect on p38 MAP kinase and ERK activity
(6, 7). Withdrawal of NGF from differentiated PC12 neuronal
cells results in persistent activation of JNK and p38 MAP kinase with inhibition of ERK activity (69). Although there are variable effects on p38 MAP kinase and ERK activities in different cell systems,
the JNK activation is persistent and shows a direct correlation with
apoptosis. Furthermore, repression of JNK activation by transfection of
a dominant negative mutant, JNK1, prevents
and UVC
irradiation-induced apoptosis (6, 7). Overexpression of a
dominant negative mutant of upstream kinase MEK kinase 1 (MEKK1) for
JNK inhibits apoptosis induced by deprivation of NGF from
differentiated PC12 cells (69). In the present study,
transfection of a dominant negative mutant of SEK, an upstream kinase
for JNK, also blocks TG-induced apoptosis. All of these observations
indicate that sustained JNK activation is essential to induce apoptosis
in some types of cell death. The TG-induced persistent JNK activation may be produced by the continued stimulation of upstream activators of
the JNK pathway due to cellular damage by ROS or nitric oxide (13). An alternative pathway for prolonged JNK activation by TG may be the inactivation of a dual-specificity phosphatase, an enzyme
that can dephosphorylate JNK and ERK, resulting in down-regulation of
the activities (35).
Nitric oxide (NO) is an important pleiotropic molecule involved in
neurotransmission, regulation of vascular homeostasis, and effector
functions of macrophages and endothelial cells (43). NO is
derived from the oxidation of L-arginine catalyzed by
constitutive (cNOS) or inducible (iNOS) NO synthase. The cytotoxic
effects of NO were found to be associated with apoptosis in normal
cells (1, 14) and tumor cells (15, 63-65). The
mitochondria generate a significant amount of NO, whose production may
affect energy metabolism, O2 consumption, and
O2 free radical formation (16). The activity of
mitochondrial NOS is stimulated when Ca2+ is taken up by
mitochondria (17). In the present study, the activation of
JNK is related to the activation of NOS since treatment of cells with
the NOS inhibitor L-NAME blocks TG-induced JNK activation and apoptosis.
Bcl-2 is intracellularly located in the places where ROS are generated,
such as mitochondria, ER, and nuclear membranes (23). Bcl-2
inhibits ROS-induced apoptosis through regulation of an antioxidation
pathway (22, 23). There is a complex interrelationship between oxygen radical damage and intracellular Ca2+
fluxes, including evidence that oxidative damage can mobilize Ca2+ from intracellular pools located in the ER and
mitochondria (46, 50, 72). Therefore, it is interesting to
speculate that the effects of Bcl-2 on intracellular Ca2+
homeostasis and oxygen radical damage may be related. Reducing Bcl-2
expression with an antisense oligonucleotide increases the sensitivity
of the CATH.a cell line to the toxic effects of dopamine (39). Moreover, overexpression of Bcl-2 in PC12 cells can
block JNK activation induced by serum deprivation (48). It
is not known whether NO plays a role in these systems.
The activation of cysteine proteases from the caspase family appears to
be essential for apoptosis to occur (62). These enzymes
cleave their substrate(s) after certain recognition sequences ending
with an aspartate residue. At least 13 of these enzymes are known, and
they seem to cleave with different substrate specificities (62). Recently, it has been shown that activated caspase-3
(activated by genotoxin) can cleave MEKK1 into an active 91-kDa kinase
fragment (68). A mutant MEKK1 that is resistant to caspase
cleavage can block genotoxin-induced apoptosis (68). In
addition, caspase-3-like activity is essential for calphostin c-induced
activation of JNK and p38 kinase (47). Similarly in the
present study, caspase inhibitors (z-DEVD-fmk and z-VAD-fmk) were able
to block TG-induced JNK activity and apoptosis, suggesting the
requirement for caspase activity in JNK activation. Moreover, treatment
of Jurkat cells with TG resulted in the activation of caspase-3, and
this activation was blocked by Bcl-2, Bcl-XL, or caspase inhibitors.
Alterations in mitochondrial function, in particular the induction of
the MPT, are proposed to play a critical role in apoptosis (44). Cytochrome c release and mitochondrial
membrane depolarization as a result of the opening of permeability
transition pores have been proposed as early irreversible events during
apoptosis (71). Opening of the MPT pores might mark a point
of no return during the effector phase of ongoing apoptosis. Production
of nitric oxide in the mitochondria results in mitochondrial lipid
degradation and cytochrome c release (60, 61,
64). Generation of the nitric oxide may be the important event in
the mitochondria for the release of cytochrome c, which has
been found to activate caspases (28, 29, 70). Consistent
with these findings, microinjection of cytochrome c results
in apoptosis (73) that cannot be inhibited by
Bcl-XL expression (27). In addition, at least
one mitochondrial protein (AIF) released following mitochondrial
depolarization is an activator of nuclear apoptosis, presumably through
caspase activation (59). In a recent report, the induction
of the overexpression of Bax in stably transfected Jurkat cells induced
MPT, an event that is accompanied by typical features of apoptosis,
namely, cytosolic accumulation of cytochrome c, caspase
activation, cleavage of poly(ADP-ribose) polymerase, DNA fragmentation,
and cell death (49). Bcl-2 and Bcl-XL block
apoptosis by preventing cytochrome c release to the cytosol,
downstream caspase activation, reduction in

m, and AIF liberation (5, 8, 20, 28,
29, 58, 59, 69). Thus, both the loss of outer mitochondrial membrane integrity leading to cytochrome c release and inner
membrane depolarization are caspase-activating events that trigger the apoptotic cascade downstream of Bcl-2 and Bcl-X